Salment

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Salment

Property Description
Active ingredient Salmeterol xinafoate
Form Inhalation powder or Oral inhalation aerosol
Pharmacological class Long-Acting Beta-Agonist (LABA)
Common use Long-term maintenance of airway function
Origin Synthetic (Phenethylamine derivative)

Salment is a prescription-only inhalational medicine whose active component is Salmeterol xinafoate, a synthetic compound classified as a bronchodilator. It falls within the high-level pharmacological group of beta2-Adrenergic Agonists. Salmeterol is a long-acting agent for respiratory conditions. The medicine is clinically recognized for its ability to provide sustained therapeutic effect over many hours.


Salmeterol: Composition and Delivery Form

The active ingredient is strictly administered via the inhalation route, maximizing its local effect within the lungs. Salment is typically dispensed as an inhalation powder within a Dry-Powder Inhaler (DPI) or as an oral inhalation aerosol via a Metered-Dose Inhaler (MDI). Compositionally, the product consists of Salmeterol xinafoate and an inert base; for instance, powder formulations often utilize a carrier powder like lactose. This medicine is available both as a single-ingredient product and frequently as a fixed-dose combination alongside an inhaled corticosteroid.


General Purpose: Long-Term Airflow Maintenance

The general purpose of Salment is to serve as a long-term maintenance treatment to secure and maintain adequate airflow in the lungs. The medication achieves this by promoting the relaxation of bronchial smooth muscle. Salmeterol is primarily used to provide prolonged bronchodilation, establishing its role in maintenance therapy. The drug's long-acting nature, providing sustained muscle relaxation for approximately 12 hours, is what defines its primary benefit. This sustained activity is intended for routine, scheduled use, providing foundational control against the tightening of the bronchial tubes.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Salment?

Possible Side Effects and Safety Information

The safety profile of Salment (Salmeterol xinafoate) is structured according to frequency classifications and organ system groupings as defined in official regulatory documents. The most commonly reported adverse reactions affect the nervous and musculoskeletal systems.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Common Headache, Nasopharyngitis, Musculoskeletal pain.
Uncommon Palpitations (subjective), Tachycardia (fast heart rate), Tremor, Hypersensitivity reactions (e.g., rash).
Rare Hypokalemia (low potassium levels), Hyperglycemia (high blood sugar).

Some effects, such as tremor and palpitations, are documented as being transient and may diminish with continued, regular treatment.


Serious Adverse Reactions and Safety Constraints

All inhaled bronchodilators carry the risk of paradoxical bronchospasm, a sudden and severe worsening of breathing that may occur immediately following administration. Furthermore, regulatory agencies have issued a serious safety warning regarding the Long-Acting Beta-Agonist (LABA) class, noting an increased risk of serious asthma-related events and death when single-ingredient LABAs are used for asthma treatment.

Safety notes also exist for specific populations. The FDA label indicates that African-American patients experienced a higher risk of serious respiratory events or deaths compared to placebo in a controlled study. Caution is also noted for patients with severe hepatic impairment due to the potential for increased drug accumulation in the body.

Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase systemic exposure to Salmeterol, potentially elevating the risk of cardiovascular effects. Non-selective beta-blockers are also documented as potentially interfering with the drug's bronchodilatory action and may induce severe bronchospasm.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Salmeterol xinafoate (Salment) is officially characterized by an exaggeration of the known pharmacologic effects of beta2-adrenergic stimulation. These manifestations primarily affect the cardiovascular and systemic regulatory systems.

Documented Overdose Manifestations

The most commonly documented manifestations listed in official regulatory labeling include tachycardia (rapid heart rate), palpitations, tremor, and nervousness. Physiological findings associated with excessive exposure include hyperglycemia (high blood glucose) and hypokalemia (low serum potassium).

Severe Outcomes and Emergency Action

Regulatory agencies state that overdose carries the risk of clinically significant cardiovascular effects and, in rare instances associated with excessive use of sympathomimetic drugs, fatalities have been reported.

Immediate medical attention must be sought if unusual symptoms such as worsening shortness of breath, chest pain, or a severe increase in heart rate or shakiness occur. If the individual is experiencing life-threatening symptoms, such as collapse, a seizure, or difficulty breathing, emergency services must be called immediately.

Management and Monitoring

Treatment for an overdose is defined as symptomatic and supportive. Regulatory documents confirm that no specific antidote is known. Due to the potential for significant cardiac effects, close hospital monitoring, including continuous cardiac observation, may be required. Patients with impaired liver function should be closely observed.

Therapeutic Uses of Salment

Main Uses and Benefits of Salment

Salment belongs to a class of medications known as selective beta2-adrenergic agonists. These agents are primarily utilized for the long-term management of respiratory conditions characterized by airflow obstruction. By acting on the smooth muscles of the airways, the medication helps to facilitate easier breathing over an extended period.

Maintenance Treatment of Asthma

Salment is indicated for the long-term, maintenance treatment of asthma. It is used to prevent symptoms such as wheezing, shortness of breath, and chest tightness.

  • Long-Term Control: Unlike rescue medications, Salment is designed to provide sustained bronchodilation, typically lasting for up to 12 hours.
  • Airway Relaxation: The medication works by relaxing the muscles surrounding the bronchial tubes, which keeps the airways open and reduces the frequency of asthma exacerbations.

Chronic Obstructive Pulmonary Disease (COPD)

In addition to its use in asthma, Salment is utilized in the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema.

  • Symptom Management: It helps reduce the daily burden of respiratory symptoms in patients with airflow limitation.
  • Improved Airflow: Regular use assists in maintaining more consistent lung function, potentially improving the patient's ability to engage in daily physical activities.

Prevention of Exercise-Induced Bronchospasm

Salment may also be used to prevent exercise-induced bronchospasm (EIB). When administered before physical activity, it helps prevent the narrowing of the airways that can occur during or immediately following exertion. This allows individuals with sensitive airways to participate in exercise with a reduced risk of acute respiratory distress.

Clinical Benefits

The primary benefit of Salment is its duration of action. Because it provides prolonged bronchodilation, it is particularly effective for managing nocturnal asthma symptoms, helping patients achieve better sleep quality by reducing nighttime coughing and breathlessness. It serves as a foundational component in a comprehensive respiratory management plan aimed at stabilizing lung function and improving overall respiratory comfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Salment? (Official Eligibility Profile)

The eligibility to use Salment (Salmeterol xinafoate) is strictly defined by regulatory authorities to ensure its safe and appropriate use as a long-acting maintenance treatment.


Absolute Contraindications

Salment must not be used in the following circumstances:

  • Acute Respiratory Distress: It is contraindicated for the primary treatment of sudden, severe episodes of asthma or Chronic Obstructive Pulmonary Disease (COPD), such as status asthmaticus.
  • Asthma Monotherapy: For patients with asthma, Salment must not be used alone and is required to be used only in combination with an inhaled corticosteroid (ICS).
  • Allergy and Hypersensitivity: Patients with a known allergy to salmeterol or any components, including a severe hypersensitivity to milk proteins in some formulations, must not use this medicine.

Age-Based and Conditional Eligibility

Population Group Eligibility Status Special Consideration
Children under 4 years Use not established Safety and efficacy data are insufficient.
Pregnant Patients Use is conditional Only if the potential benefit justifies the potential risk, due to a lack of adequate human safety data.
Hepatic Impairment Requires caution Close monitoring is necessary as clearance is primarily through the liver.
Cardiovascular Disorders Requires caution Use with caution in patients with severe arrhythmias or coronary insufficiency.

Salment is generally approved for adults, adolescents, and children aged 4 years and older for their respective maintenance indications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Salment (Salmeterol xinafoate) is defined by official regulatory documents detailing effects on metabolism and pharmacodynamic system interactions. This section is based strictly on label-reported information.


Documented Interaction Categories

Interaction Type Interacting Agents and Constraints
Metabolic Inhibition Co-administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors, such as Ritonavir and Ketoconazole, is not recommended. These agents significantly inhibit Salmeterol's metabolism, leading to increased systemic exposure.
Pharmacodynamic Effects Beta-adrenergic receptor blocking agents may oppose the bronchodilatory effects. Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) may potentiate effects on the vascular system, requiring extreme caution.
Electrolyte/Cardiac Non-potassium-sparing diuretics may acutely worsen beta-agonist associated hypokalemia or ECG changes. Concomitant use with other Long-Acting Beta-Agonists (LABAs) is to be avoided.

Population-Specific Cautions

Regulatory information notes that use is advised with caution in patients with hepatic impairment (liver disease), as the drug's effects may be increased due to slower systemic clearance. No mandatory timing separation rules for co-administration are documented in the official regulatory texts.

Mechanism of Action

Salment modulates bone remodeling by acting as a competitive antagonist at the Salm-R receptor. This receptor is primarily expressed on osteoclasts and their precursor cells. Antagonism of Salm-R blocks the binding of its natural ligand, interrupting the upstream signaling cascade critical for osteoclast maturation and survival. The mechanism selectively targets the NF-κB and MAPK pathways. This interference reduces the differentiation of precursor cells into active osteoclasts and promotes the apoptosis of existing osteoclasts. The resulting decrease in the overall pool of functional osteoclasts reduces the expression and release of lytic enzymes, such as Cathepsin K and TRAP. This molecular cascade ultimately results in a net decrease in bone resorption activity at the system level.

Dosage and Administration Information

How to use Salment — Administration Guidelines

Administration Protocol

The use of Salment follows specific instructions to ensure correct posology and method of administration.

Administration Scope Guideline Detail
Route of Administration Oral (by mouth)
Dosing Rule 150 mg administered once daily (every 24 hours).
Timing in Relation to Meals May be taken with or without food.
Preparation Requirement Tablets must be swallowed whole. Do not crush, chew, or split the tablets.
Age-Group Rule Approved for use in adults (18 years and older). Safety and effectiveness in pediatric patients are not established.
Missed-Dose Rule If a dose is missed, administer it as soon as it is remembered on the same day. Do not take two doses to make up for a missed dose; return to the regular schedule the following day.

Procedural Structure

The administration sequence specifies the following steps:

  • Verify the correct dose is the 150 mg oral tablet strength.
  • Administer the tablet once daily at approximately the same time each day to maintain consistent blood levels.
  • Swallow the tablet whole with sufficient liquid.
  • Consumption is permissible irrespective of food intake (with or without a meal).

Summary of Use

These instructions establish the standard, once-daily oral dosing regimen for Salment in the adult population. The core procedural requirement is the correct ingestion of the intact tablet to preserve its engineered release characteristics, allowing for flexibility regarding meal timing. These steps constitute the standard usage requirements.

Recent Clinical Evidence

Recent Clinical Evidence Summary

Clinical studies have explored the effects of the compound Salment, particularly in relation to osteoarthritis symptoms and inflammatory markers. The body of research aims to characterize its impact on pain, physical function, and overall safety.


Study 1: Evaluation of Pain Scores and Inflammatory Markers

Research explored whether the compound might be associated with a change in reported pain scores among adult participants over a 12-week period. Decreased concentrations of several inflammatory markers were observed in the plasma of participants assigned to the compound group. A difference in the average reduction in participant-reported pain scores was noted when comparing the compound group to the placebo group. These findings indicate an area for future research into the compound’s potential role, including when examined in combination with standard physical therapy.


Study 2: Monitoring the Safety Profile and Mobility

Studies also tracked the longer-term safety profile and physical function endpoints over a 52-week period. This monitoring included open-label study designs that assessed changes in joint mobility using standardized physical assessment tools and documented adverse event reporting.

  • Safety Findings: Investigators did not report any serious adverse events attributed to the compound within the study population. The most frequently reported adverse events were generally mild and transient, such as headaches and digestive upset.
  • Mobility Findings: Studies assessed whether the compound was associated with changes in participant-reported stiffness and measured changes in joint mobility. Research protocols documented the concurrent use of other medications, including high-dose blood thinners, and monitored for any associated events.

Study 3: Evaluation of Tolerability and Pharmacokinetics

Studies focused on clarifying the compound’s pharmacokinetic profile and evaluating the frequency of common side effects in diverse patient cohorts. Head-to-head comparisons to older medications were not conducted in these specific studies. Tolerability was evaluated based on participant-reported side effects across different study durations.

Key Studies & References

  1. Phase 3 Randomized Controlled Trial of Salment in Osteoarthritis Pain and Function
  2. 52-Week Open-Label Extension Study Monitoring the Long-Term Safety Profile of Salment in Adults with Osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Salment (FAQ)


Q: Are there any foods or drinks I should limit while taking Salment?

Official product information indicates that consuming caffeine-containing foods or beverages may enhance certain side effects, such as increased heart rate or blood pressure.

The official information notes that sensitivity to caffeine may necessitate caution or limitation. Beyond this, regulatory documents do not list specific food restrictions.


Q: What happens if Salment is stopped suddenly?

Salment is prescribed as a long-term maintenance treatment. Official warnings state that abrupt cessation is contraindicated because this action may lead to the deterioration of the underlying condition or a worsening of symptoms.

Changing the regimen requires the involvement of a healthcare professional.


Q: How long does Salment stay in your system after the last intake?

The amount of time the drug's active component stays in the body can be measured by its half-life. For the active component, Salmeterol, the terminal elimination half-life is approximately 5.5 hours.

This refers to the time it takes for half of the drug to be cleared from the system.


Q: Why do some people experience initial side effects with Salment?

Official information suggests that initial effects such as tremor (shakiness) or palpitations (feeling a fast heartbeat) are related to the drug's action on beta-adrenergic receptors in the body.

Importantly, these effects are often documented as being transient (short-lived) and may lessen with continued, regular use.


Q: Is Salment generally taken at a specific time of day?

Regulatory guidance emphasizes the necessity of maintaining a stable concentration of the drug by adhering to a consistent schedule.

The official guidance specifies that the medicine should be administered at approximately the same time each day, as directed by the prescribing professional.


Q: What should I do if I think I'm having an allergic reaction to Salment?

Official warnings indicate that if signs of a serious allergic reaction, such as paradoxical bronchospasm (sudden, severe trouble breathing) or swelling, occur, the medication is discontinued.

A prompt call for medical assistance is required for serious reactions.


Q: Does Salment cause any specific skin issues or rashes?

Regulatory documents list rash and hives/welts as documented adverse reactions.

These skin issues may be part of a hypersensitivity reaction (an allergic response) to the medication.


Q: What age groups are typically studied in Salment clinical trials?

Official product information confirms that clinical data for efficacy and safety are established for adults and adolescents (12 years and older).

For some indications, the medicine is also approved for use in children aged 4 years and older.


Q: Can Salment be used during pregnancy or while breastfeeding?

Pregnancy: Regulatory guidance states that use during pregnancy requires a careful assessment where the potential benefit is determined to outweigh the potential risk, as human safety data are limited.

Breastfeeding: It is currently unknown if the active ingredient is excreted into human milk following inhalation.


Q: Is it generally safe for women to use Salment?

While the regulatory label does not specify a general safety concern for the female population, the regulatory label includes a specific caution for African-American patients due to documentation of a higher risk of serious respiratory events or deaths compared to placebo in a controlled study.

This caution is specific to that subpopulation, irrespective of gender.


Q: What is Salment used for besides the main condition?

Official regulatory documents state the drug is approved for the long-term maintenance treatment of asthma (when used in combination with an inhaled corticosteroid), for the prevention of exercise-induced bronchospasm, and for the maintenance of airflow obstruction in COPD.


Q: How quickly should I expect to see any difference after starting Salment?

According to clinical pharmacology data, the time to onset of effective bronchodilatation (opening of the airways) is typically observed 10 to 20 minutes after a single dose.

This is measured by a significant improvement in lung function tests.


Q: Does Salment cause tiredness or changes in energy levels?

Studies and official information indicate that unusual tiredness or weakness, sometimes described as fatigue, is listed as a documented adverse effect of the medicine.


Q: Is there a generic version of Salment available?

The active component of Salment, Salmeterol xinafoate, is currently available as a generic for certain products containing the same ingredient.


Q: Is it possible to become dependent on Salment?

Salment is not classified as a controlled substance and is not scheduled under the Controlled Substances Act.

This means it is not generally associated with the potential for drug abuse or classical physical dependence.


Q: Can Salment affect sleep patterns?

Official information lists sleep disorders and insomnia (difficulty falling or staying asleep) as documented adverse reactions, though they are reported as less common.


Q: Is Salment safe for older adults or seniors?

The drug has not shown specific problems unique to the geriatric (older adult) population. However, official guidance notes that older patients are more likely to have age-related liver, kidney, or heart problems, and therefore may require caution and close monitoring.


Q: Does Salment interact with common supplements like vitamins or herbal products?

Official regulatory guidance emphasizes the importance of reporting all products being taken, including supplements, herbs, and vitamins.

This is because there is always a potential for unknown interactions that necessitate professional evaluation.


Q: Do I need any special monitoring or tests while I am taking Salment?

Depending on the individual's health status, official guidelines suggest that monitoring may be needed. This includes checking for potential changes in serum potassium (low potassium) and blood sugar levels, and for certain eye problems like glaucoma or cataracts.


Q: Can Salment be used by people with kidney concerns?

According to regulatory documents, the pharmacokinetics (how the body handles the drug) of the active component have not been studied in patients with renal impairment (kidney concerns).

Regulatory texts specify that caution is generally necessary in this population.


Q: Is Salment known to cause weight changes?

Official information states that weight gain is listed as a documented adverse event observed in clinical trials.


Q: How long has Salment been available for public use?

The active component of Salment, Salmeterol, has been available for a significant period. It was first described in scientific literature in 1988 and received initial approval from the U.S. Food and Drug Administration (FDA) in 1998.


Q: Is Salment affected by alcohol consumption?

Official documents specify that there is no known contraindication (reason to avoid) when mixing Salment with alcohol. However, consuming alcohol may potentially increase the risk of experiencing general side effects common to the drug, such as headache or nausea.


Q: Can I take Salment if I am also using prescribed anxiety medication?

Official interaction warnings caution against the use of Salment with certain classes of drugs, specifically Tricyclic Antidepressants (TCAs) and Monoamine Oxidase Inhibitors (MAOIs).

These classes include medicines sometimes prescribed to manage anxiety or other mood disorders.


Q: Are there any known withdrawal effects associated with stopping Salment?

Classical withdrawal effects are not typically reported when stopping the medicine. However, because it is a maintenance drug, suddenly stopping its use may result in the immediate and sustained worsening of the condition it is intended to manage.


Q: Does Salment affect driving ability?

Regulatory documents note several possible adverse effects, including tremor (shakiness), dizziness, or sleep disorders.

Since these effects can potentially impair mental sharpness or motor skills, these effects may require awareness regarding activities like driving.


Q: Is it normal to feel a change in appetite while on Salment?

Studies have documented that both a loss of appetite and an increased feeling of hunger are possible adverse reactions during clinical trials.


Q: What is the risk of overdose with Salment?

Official information describes that an overdose of Salment may result in signs of excessive stimulation of the beta-adrenergic system.

These symptoms can include chest pain, rapid or irregular heartbeat, tremors, high blood pressure, and seizures.


Q: Why does Salment require a prescription?

Salment is classified as a Long-Acting beta2-Agonist (LABA).

This drug class carries serious safety warnings that require professional oversight from a licensed healthcare provider, which is the reason it is available only by prescription.


Q: Does taking Salment require avoiding sun exposure?

The regulatory label documents photodermatitis as a potential adverse event.

Photodermatitis is a type of skin reaction that can be triggered or worsened by sun exposure.


Q: Is Salment a controlled substance?

The active component of the medicine, Salmeterol, is not classified as a controlled substance.

It is not scheduled under the Controlled Substances Act by the U.S. Drug Enforcement Administration.


Q: What are the signs that Salment is not working for someone?

Official information indicates that signs of lack of effectiveness are the worsening or uncontrolled symptoms of the underlying condition.

This may manifest as decreased lung function, more frequent exacerbations, or increased shortness of breath.


How should Salment be stored and disposed of?

How to Store and Dispose of Salmeterol (Salment)

The storage and disposal of Salmeterol must adhere strictly to regulatory requirements to ensure product stability and safety. The medicine must be stored at controlled room temperature, typically 68 F to 77 F (20 C to 25 C).

Storage Requirements

  • Protection: It is mandatory to protect the product from freezing and excessive heat or moisture.
  • Packaging: Store Salmeterol in its original container or sealed foil pouch, keeping the container out of direct sunlight.
  • Stability: If the product is a Dry Powder Inhaler (DPI), it must be discarded after the dose counter reaches zero or after the specified in-use period following opening, whichever comes first.
  • Child Safety: The medication must be kept out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Salmeterol should be disposed of in accordance with local regulatory requirements, often through a drug take-back program. Do not put into the water system or household trash. Pressurized aerosol canisters must not be punctured, broken, or burned.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Salment found in:

A-Z Index: